Deals
Revolution Doubles Offering to $2B at $142 After Daraxonrasib Phase 3 Win
Revolution Medicines is raising $2 billion in a stock offering priced at $142 per share, up from the $1 billion it announced Monday, hours after reporting…
Deals — Page 4
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Revolution Medicines Prices Record Raise, Biotech's Biggest Since Pandemic
Revolution Medicines just priced a public equity raise, the largest single biotech offering since the Covid-19 pandemic.
Deals
Sold for $1.55B: Daiichi Sankyo's OTC Unit Goes to Suntory
Daiichi Sankyo sold its consumer health unit to Suntory Holdings for 246.5 billion yen, roughly $1.55 billion, in a staged transfer that kicks off this June…
Deals
Biogen Paid $5.6B for Apellis; Filing Confirms Deal Terms
Biogen paid $5.6B for Apellis, and a new SEC filing confirmed the deal details CEO Chris Viehbacher has been engineering: a company that doesn't grow on…
Deals
Bain Built $300M Beeline Medicines on 5 BMS Autoimmune Programs
Bain Capital put $300 million into Beeline Medicines at launch, licensing five autoimmune programs from Bristol Myers Squibb to build its next specialty…
Deals
Alamar Biosciences Files $159M IPO on 196% Revenue Growth
Alamar Biosciences wants $159 million from public markets, pricing 9.4 million shares at $15 to $17 apiece for a Nasdaq listing under "ALMR.
Deals
Click Therapeutics Cut More Than a Quarter of Staff After Series D
Click Therapeutics raised Series D funding, then cut more than a quarter of its workforce shortly after.
Deals
AbbVie Bought Two NaV1.8 Pain Assets from Haisco for $745M
AbbVie bought ex-China rights to two NaV1.8 sodium channel pain inhibitors from Beijing-based Haisco Pharmaceutical for up to $745 million.
Deals
Kailera Files $528.5M Nasdaq IPO to Fund Four GLP-1 Obesity Drugs
Kailera filed for a $528.5 million Nasdaq IPO, pricing 33.33 million shares at $14 to $16 each.
Deals
Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B
Regeneron put $40 million on the table Sunday to partner with Telix Pharmaceuticals, the Australian biotech with one of the more active radiopharmaceutical…
Deals
Counted $700M in Benko Losses, Julius Baer Now Counts CFO Days
Julius Baer has been counting losses for two years.
Deals
Blackstone Files $2B IPO for AI Data Center Buyer
Blackstone filed confidential IPO paperwork with U.S. regulators to raise $2 billion for a dedicated acquisition vehicle targeting data centers, Bloomberg…
Deals
Novo Loses GLP-1 Pioneer Lotte Bjerre Knudsen to Retirement
Novo Nordisk is losing a key obesity figure.
Deals
Shionogi Wins $119M BARDA Contract for Fetroja
Shionogi has been awarded a $119 million contract from BARDA for Fetroja, a direct government commitment to the drugmaker's drug.
Deals
Closed Above Target, Jeito Capital Fund II Hits €1.6B AUM
Jeito Capital closed Jeito II at more than €1bn, lifting the firm's total AUM to €1.6bn.
Deals
BARDA Cut $482m Shionogi Deal for US Antibiotic Capacity
BARDA paid $482m to get Fetroja made on US soil.
Deals
Paid $20M Upfront, Roche Extends C4T Molecular Glue Deal
Roche is paying $20 million upfront for access to two degrader-antibody conjugate (DAC) programs from C4 Therapeutics, with more than $1 billion in…
Deals
Polygon Targets $50M-$100M Equity Round as Token Sheds 90%
Polygon Labs seeks $50M-$100M in equity to build its Open Money Stack stablecoin platform, a bet on payments as its native token shed 90% of its value.
Deals
Steve Ubl Steps Down as PhRMA Chief Amid Drug Pricing Battle
PhRMA leader Steve Ubl plans to step down at a pivotal moment for pharma's most powerful DC trade group, Endpoints News reports.
Deals
Gilead Spends $14.77B on Three Deals, Then Hits Pause
Gilead bought Arcellx, Ouro, and Tubulis for $14.77B in under ten weeks. CFO says further big deals are unlikely this year, but the door stays open.
